Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells

Thuy, Pham Xuan; Bao, Tran Duc Duy; Moon, Eun‐Yi

doi:10.1016/j.biopha.2022.113021

Cited by 20 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UDCA reportedly can substantially impair binding of SARS‐CoV‐2 spike protein to ACE2 in Beas‐2B cells 10 . Furthermore, UDCA‐mediated ACE2 downregulation reduces susceptibility to SARS‐CoV‐2 infection in vitro, in vivo and in perfused human lungs and livers 4 .…”

Section: Discussionmentioning

confidence: 99%

“…CoV-2 spike protein to ACE2 in Beas-2B cells. 10 Furthermore, UDCA-mediated ACE2 downregulation reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in perfused human lungs and livers. 4 The temporal relationship in patients between withdrawal of UDCA and return to normal ACE2 expression and function, however, is not clear.…”

Section: Udca Reportedly Can Substantially Impair Binding Of Sars-mentioning

confidence: 99%

See 1 more Smart Citation

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Liu

Wang

2023

Liver International

View full text Add to dashboard Cite

Background and AimsA recent study suggested that administration of ursodeoxycholic acid (UDCA) at dosages usually employed clinically may reduce rates of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. A recent surge of SARS‐CoV‐2 omicron infection in China allowed study of whether UDCA administration reduced susceptibility to SARS‐CoV‐2 infection in children with liver disease.MethodsThrough WeChat groups, a questionnaire was distributed to families (n = 300) in which a child had been admitted to our liver service in the past 5 years. Among the families/households in which someone was infected with SARS‐CoV‐2, the proportion in which a child taking UDCA was infected was compared with the proportion in which a child not taking UDCA was infected.ResultsOf the 300 questionnaire answers, 280 (93.3%) were valid. SARS‐CoV‐2 infection was confirmed in 226 families (80.7%): 146 children were taking UDCA (10‐20 mg/kg/day) and 80 children were not taking UDCA. SARS‐CoV‐2 infection was confirmed in 95 children taking UDCA (65.1%) and in 51 children not taking UDCA (63.8%) (p = 0.843); SARS‐CoV‐2 infection was suspected in 23 children taking UDCA (15.8%) and in 11 children not taking UDCA (13.8%) (p = 0.687).ConclusionsThese results indicate that UDCA administration does not reduce susceptibility to SARS‐CoV‐2 infection in children with liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Udca Reportedly Can Substantially Impair Binding Of Sars-mentioning

confidence: 99%

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Liu

Wang

2023

Liver International

View full text Add to dashboard Cite

show abstract

“…[31] In addition, UDCA significantly interferes with the binding of S protein to ACE2 in BEAS-2B human bronchial epithelial cells and suppresses abnormal airway epithelial cell migration. [32] Docking simulations have indicated that UDCA blocks the binding of RBD and ACE2 in a dose-dependent manner. [33,34] Guggulsterone, another FXR antagonist, has also been shown to be a potential inhibitor of SARS-CoV-2 ADP ribose phosphatase.…”

Section: Decreasing Ace2 Expression Could Block Sars-cov-2 Infection ...mentioning

confidence: 99%

Can Ursodeoxycholic Acid Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Reduce the Coronavirus Disease 2019 Severity? Current Knowledge and Unresolved Issues

et al. 2023

View full text Add to dashboard Cite

A recent study revealed that the inhibition of the farnesoid X receptor using ursodeoxycholic acid (UDCA) significantly reduces angiotensin-converting enzyme 2 (ACE2) expression. Therefore, considerable attention has been paid to the use of UDCA to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and reduce the severity of the disease. This review comprehensively summarizes the role of ACE2 in SARS-CoV-2 infection and the potential role and mechanisms of UDCA in the prevention of SARS-CoV-2 infection or reinfection. It also discusses unresolved issues and the potential use of UDCA in the treatment of patients with coronavirus disease.

show abstract

“…Ursodeoxycholic acid (UDCA), which modulates FXR expression, lessens circulating ACE2 levels in vivo, thereby it decreases the severity of hospitalized Covid-19 patients (Brevini et al 2021a ). However, UDCA reduces airway inflammation through the modulation of FXR expression and the development of eosinophilic inflammation (Thuy et al 2022 ). Brevini and colleagues revealed that FXR antagonist O07 could effectively manage Covid-19 (Brevini et al 2021b ).…”

Section: Fxr and Covid-19mentioning

confidence: 99%

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

The causative agent of CoV disease 2019 is a new coronavirus CoV type 2, affecting the respiratory tract with severe manifestations (SARS-CoV-2). Covid-19 is mainly symptomless, with slight indications in about 85% of the affected cases. Many efforts were done to face this pandemic by testing different drugs and agents to make treatment protocols in different countries. However, the use of these proposed drugs is associated with the development of adverse events. Remarkably, the successive development of SARS-CoV-2 variants which could affect persons even they were vaccinated, prerequisite wide search to find efficient and safe agents to face SARS-CoV-2 infection. Obeticholic acid (OCA), which has anti-inflammatory effects, may efficiently treat Covid-19. Thus, the goal of this perspective study is to focus on the possible medicinal effectiveness in managing Covid-19. OCA is a powerful farnesoid X receptor (FXR) agonist possessing marked antiviral and anti-inflammatory effects. FXR is dysregulated in Covid-19 resulting in hyper-inflammation with concurrent occurrence of hypercytokinemia. Interestingly, OCA inhibits the reaction between this virus and angiotensin-converting enzyme type 2 (ACE2) receptors. FXR agonists control the expression of ACE2 and the inflammatory signaling pathways in this respiratory syndrome, which weakens the effects of Covid-19 disease and accompanied complications. Taken together, FXR agonists like OCA may reveal both direct and indirect impacts in the modulation of immune reaction in SARS-CoV-2 conditions. It is highly recommended to perform many investigations regarding different phases of the discovery of new drugs.

show abstract

Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells

Cited by 20 publications

References 31 publications

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children

Can Ursodeoxycholic Acid Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Reduce the Coronavirus Disease 2019 Severity? Current Knowledge and Unresolved Issues

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection

Contact Info

Product

Resources

About